
Second Annual Meeting of the Oligonucleotide Therapeutics Society
Thursday, October 19, 2006 - Saturday, October 21, 2006
Oligonucleotide-based gene-silencing techniques are emerging as important tools for targeting specific genes for research and innovative therapeutics. This meeting, sponsored by the New York Academy of Sciences and the Oligonucleotide Therapeutics Society, will integrate basic science, drug discovery, and preclinical and clinical research, so that those working in academic and industry settings can develop a mutual understanding of the various technologies offered and their applications in both scientific research and as therapeutic agents.
Organizing Committee:
- Fritz Eckstein
- Michael Gait
- Alan Gewirtz
- Gunther Hartmann
- Ryszard Kole
- Arthur Krieg
- Brett Monia
- John Rossi
- Hermona Soreq
- Thomas Tuschl
Special sessions are devoted to:
- Cell biology and enzymology of mRNA metabolism and oligonucleotide function
- Oligonucleotide synthesis and technologies
- Gene targeting
- Immunomodulation
- Novel and alternative gene targeting technologies
Graduate Students and Postdocs:
Join us for lunch on Saturday during the conference at a Roundtable to discuss careers in industry. Industry leaders from various companies attending the conference will be on hand to discuss and answer questions regarding the types of jobs available and how to prepare for jobs in industry. Bring your CV.
Sponsored by Science Alliance.
We gratefully acknowledge the support of:
Gold Sponsor
- ChemGenes
Silver Sponsors
- Alynylam Pharmaceuticals
- Coley Pharmaceutical Group
- Isis Pharmaceuticals
- Pfizer
Bronze Sponsors
- Acuity Pharmaceuticals
- Agilent Technologies - Boulder
- Avecia
- Biosearch Technologies, Inc.
- Calando Pharmaceuticals
- Dainippon Sumitomo Pharma Co., Ltd.
- Dharmacon
- Ercole Biotech, Inc.
- Gene Tools
- Glen Research
- Integrated DNA Technologies
- Invitrogen, Koken Co., Ltd.
- Nature Publishing Group
- Novartis
- OSI Eyetech
- Pachyonychia Congenita Project
- Qiagen
- RNAi.net
- Rosetta Inpharmatics/Merck Research Laboratories
- Sanofi Aventis
- Sirna Therapeutics
- Topigen Pharmaceuticals
- U.S. Army